GURU.Markets stock price, segment price, and overall market index valuation
The company's share price OpGen Inc.
OpGen's stock, a molecular diagnostics company, reflects its struggle to commercialize tests for detecting antibiotic-resistant infections. Its price trajectory is volatile and depends on sales news, partnerships, and the need for additional funding.
Share prices of companies in the market segment - Pharma infections
OpGen, Inc. is a molecular diagnostics company developing tests to detect and combat antibiotic-resistant infections. We've categorized it as "Pharma: Infections." The chart below shows how investors value companies solving the superbugs problem.
Broad Market Index - GURU.Markets
OpGen, Inc. is a molecular diagnostics company developing tests to detect and combat antibiotic-resistant infections. We've categorized it as "Pharma: Infections." The chart below shows how investors value companies solving the superbugs problem.
Change in the price of a company, segment, and market as a whole per day
OPGN - Daily change in the company's share price OpGen Inc.
OpGen, Inc.'s daily share price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about the development of its diagnostic tests to combat antibiotic-resistant bacteria.
Daily change in the price of a set of shares in a market segment - Pharma infections
OpGen develops molecular diagnostics and data analytics solutions to combat antibiotic-resistant infections. This healthcare sector is important, but commercializing its products is challenging. The chart below illustrates the volatility in this niche, helping to assess OPGN's performance.
Daily change in the price of a broad market stock, index - GURU.Markets
OpGen is a company specializing in diagnosing antibiotic-resistant infectious diseases. The company's shares are reacting to news of its tests being accepted by the medical community. This specific volatility feeds into the overall market movement.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization OpGen Inc.
OpGen, Inc.'s year-over-year performance tells the story of its struggle to conquer the infectious disease diagnostics market. Its market cap change over the past 12 months reflects its success in advancing its platforms for detecting antibiotic-resistant bacteria, as well as its ongoing need for funding to continue its operations.
Annual dynamics of market capitalization of the market segment - Pharma infections
OpGen, a diagnostics company, is focused on combating antibiotic resistance. This chart shows how its niche technology, market expansion efforts, and reliance on physician adoption of its method impact its performance in the medical device sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
OpGen, a molecular diagnostics and bioinformatics company focused on combating antibiotic resistance, is solving a global healthcare problem. Its year-over-year market capitalization reflects its success in selling its tests and platforms to hospitals.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization OpGen Inc.
OpGen is a molecular diagnostics company focused on combating antibiotic-resistant bacteria. Its monthly performance reflects progress in commercializing its rapid diagnostic platform.
Monthly dynamics of market capitalization of the market segment - Pharma infections
OpGen is a molecular diagnostics company developing tests to detect and combat antibiotic-resistant bacteria. This is one of the most pressing issues in modern healthcare. The graph below shows the overall dynamics in the pharmaceutical sector, reflecting the critical need for new tools to combat superbugs.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of diagnostic companies working in critical areas like antibiotic resistance can move on their own news. The chart below shows the overall sentiment. Does OpGen, Inc. have a life of its own, or does its small size make it vulnerable to market fluctuations?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization OpGen Inc.
OpGen, a company fighting antibiotic resistance, shares reflect this global threat on a weekly basis. Their price movements reflect the introduction of their diagnostic tests, which help quickly identify resistant bacteria, and general awareness of the problem.
Weekly dynamics of market capitalization of the market segment - Pharma infections
OpGen develops solutions for rapid infection diagnostics and antibiotic resistance detection. This is a critically important area of medicine. The chart will help you compare its weekly performance with the sector and understand how the market views its technologies in the fight against the global problem of antibiotic resistance.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
OpGen is a company in the medical diagnostics sector. Shares of such companies may be less dependent on general economic cycles. This chart will help us understand whether OpGen shares are living in a world of clinical trials, or whether the overall market environment still influences their stock price.
Market capitalization of the company, segment and market as a whole
OPGN - Market capitalization of the company OpGen Inc.
OpGen's market capitalization chart tells the story of a molecular diagnostics company battling antibiotic resistance. Its decline reflects the challenges of commercializing diagnostic platforms and intense competition. Its performance reflects the company's struggle to survive and find its place in the market.
OPGN - Share of the company's market capitalization OpGen Inc. within the market segment - Pharma infections
OpGen specializes in molecular diagnostics for infectious diseases. The company's market capitalization is small, reflecting intense competition and commercialization challenges. The chart shows how the market evaluates its technologies in the fight against the growing problem of antibiotic resistance.
Market capitalization of the market segment - Pharma infections
OpGen is a company focused on molecular diagnostics and bioinformatics to combat antibiotic-resistant infections. The chart below shows the market capitalization of this sector. Its dynamics reflect one of the most serious threats to global healthcare, highlighting the importance of OpGen's technologies.
Market capitalization of all companies included in a broad market index - GURU.Markets
OpGen develops solutions to diagnose and combat antibiotic-resistant bacteria. Its market cap reflects the bet that its technologies will help solve one of the most serious threats to global healthcare. Its performance reflects the market's confidence in its ability to address this problem.
Book value capitalization of the company, segment and market as a whole
OPGN - Book value capitalization of the company OpGen Inc.
OpGen's book value is its capital, laboratories, and platforms for molecular diagnostics and antibiotic resistance analysis. This is the tangible, scientific foundation for combating one of the main threats to global health. How has this important, yet problematic, asset changed? The chart below shows its dynamics.
OPGN - Share of the company's book capitalization OpGen Inc. within the market segment - Pharma infections
OpGen develops systems to diagnose and combat antibiotic-resistant infections, which requires R&D laboratories. The chart shows the share of these tangible assets, reflecting the physical foundation of its technological platform.
Market segment balance sheet capitalization - Pharma infections
OpGen, a molecular diagnostics company, has a moderately capital-intensive business. It requires R&D and manufacturing capabilities for its tests. The BCap_Seg chart for the medical equipment sector shows that innovation requires a material base.
Book value of all companies included in the broad market index - GURU.Markets
OpGen's balance sheet is based on its technologies and platforms for rapid infection diagnostics and antibiotic resistance detection. The company's assets include its intellectual property and laboratory equipment. The chart allows one to assess the material weight of this player in the important superbug mitigation market.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - OpGen Inc.
OpGen, Inc. is tackling the problem of antibiotic resistance. Its balance sheet is its diagnostic platforms. Its market valuation reflects the belief that its technologies will help doctors quickly select effective treatments. The chart shows how the market values its contribution to solving one of the global health threats.
Market to book capitalization ratio in a market segment - Pharma infections
OpGen, Inc. develops molecular tests and bioinformatics solutions for the rapid diagnosis and treatment of antibiotic-resistant infections. Its score on the graph reflects both the importance of this problem and the significant challenges in commercializing its products.
Market to book capitalization ratio for the market as a whole
OpGen, Inc. develops solutions to combat infections, and its value lies in its unique technologies and data. It is a classic example of a company with intangible assets. This chart helps us understand the premium investors are willing to pay for innovations in molecular diagnostics compared to the overall market.
Debts of the company, segment and market as a whole
OPGN - Company debts OpGen Inc.
OpGen, a molecular diagnostics company focused on combating antibiotic resistance, is using capital to develop and market its tests. This chart shows how the company is funding its efforts to address one of the most pressing healthcare challenges while operating in a complex and capital-intensive market.
Market segment debts - Pharma infections
OpGen is a molecular diagnostics company focused on combating antibiotic resistance. This sector requires significant investment in R&D and clinical trials. This chart shows how the company is funding its development and commercializing its products in a complex and competitive environment.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio OpGen Inc.
OpGen is a molecular diagnostics company focused on combating antibiotic resistance. This chart shows the company's reliance on debt to fund its research and commercialization of diagnostic tests. It is an indicator of its financial risk in achieving acceptance and widespread adoption.
Market segment debt to market segment book capitalization - Pharma infections
OpGen develops molecular diagnostic tests to combat antibiotic-resistant infections, one of the most serious threats to global health. This chart shows how the biotech sector uses debt for R&D, providing context for how OpGen finances its important but capital-intensive research.
Debt to book value of all companies in the market
OpGen, Inc. is developing solutions to combat antibiotic resistance, which requires investments in diagnostics and information technology. This chart, showing the overall debt burden in the market, provides context. It helps assess how the molecular diagnostics company is financing its development and how its debt strategy aligns with its goals.
P/E of the company, segment and market as a whole
P/E - OpGen Inc.
OpGen is a molecular diagnostics company developing tests to detect and combat antibiotic-resistant infections. This chart shows how the market is evaluating its solutions. The dynamics reflect the growing global threat of antibiotic resistance and hospitals' need for rapid diagnostic tools.
P/E of the market segment - Pharma infections
This chart for companies in the medical diagnostics sector serves as a benchmark for OpGen. It reflects general expectations for the growth of personalized medicine. Comparisons with it help understand how the market views OpGen's platform for combating antibiotic resistance and whether it believes it can find a niche in this challenging market.
P/E of the market as a whole
OpGen is a molecular diagnostics company developing tests to detect antibiotic-resistant infections. Its valuation is a bet on its technology. It is not tied to general economic cycles, but depends on its ability to demonstrate the accuracy of its tests and address the pressing problem of antibiotic resistance.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company OpGen Inc.
For OpGen, Inc., a company specializing in infectious disease diagnostics, this chart illustrates market expectations for the future adoption of its tests. It reflects forecasts for the growing problem of antibiotic resistance and hospitals' need for fast and accurate diagnostic solutions.
%20P%2FE%20OpGen%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-OpGen-Inc.&v=1772513664355 "Chart of the company's future (projected) P/E OpGen Inc.")
Future (projected) P/E of the market segment - Pharma infections
OpGen is a molecular diagnostics company that develops and markets tests for the rapid detection and analysis of multidrug-resistant bacteria. The chart shows forecasts for the sector. This allows one to assess how the market perceives OpGen's ability to combat the growing threat of superinfections and implement its tests in hospital practice.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-infections&v=1772513664435 "Future (projected) P/E graph of the market segment - Pharma infections")
Future (projected) P/E of the market as a whole
OpGen, Inc. provides molecular diagnostic tests to combat antibiotic resistance, a global health problem. The company's success depends on the adoption of its tests in hospitals. This market sentiment graph influences the valuation of diagnostic companies solving important but complex medical problems.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513664448 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit OpGen Inc.
OpGen, Inc. provides molecular diagnostic tests and bioinformatics solutions to combat antibiotic-resistant infections. Profits depend on the adoption of its technologies in hospitals. This chart illustrates the uphill battle to commercialize solutions for one of the most serious threats to global health.
Profit of companies in the market segment - Pharma infections
OpGen is a molecular diagnostics company developing tests to detect and combat antibiotic-resistant infections. This graph, which shows the sector's profitability, illustrates the seriousness of the global problem of antibiotic resistance. Their technologies help doctors quickly identify the right treatment, saving lives and slowing the spread of superbugs.
Overall market profit
OpGen, Inc. develops and markets molecular diagnostic tests to combat antibiotic-resistant infections, one of the most serious threats to global health. Demand for its products depends on hospitals and governments recognizing this problem. The company's business is less dependent on general economic cycles, as shown in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company OpGen Inc.
OpGen, Inc. develops and markets molecular diagnostic tests and software to combat antibiotic-resistant infections. Its products help hospitals quickly identify dangerous bacteria. This chart reflects analysts' predictions for the adoption of their technologies in hospitals to combat one of the main threats to global health.
%20profit%20of%20the%20company%20OpGen%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-OpGen-Inc.&v=1772513664643 "Graph of future (projected) profit of the company OpGen Inc.")
Future (predicted) profit of companies in the market segment - Pharma infections
OpGen is a molecular diagnostics company focused on combating antibiotic resistance by providing rapid infection detection tests. Growth depends on the adoption of its technologies in hospitals. This chart for the medical diagnostics sector reflects overall growth expectations for the infectious disease testing market.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-infections&v=1772513664669 "Graph of future (predicted) profits of companies in a market segment - Pharma infections")
Future (predicted) profit of the market as a whole
OpGen is a molecular diagnostics company focused on combating antibiotic-resistant infections. The overall profit forecast, reflected in this chart, indirectly influences government healthcare priorities. The threat of pandemics and crises may stimulate investment in such technologies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513664690 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - OpGen Inc.
OpGen is a molecular diagnostics company developing tests to combat antibiotic resistance. This chart shows how investors value its revenue from sales of tests and analytical platforms. It reflects the growing global concern about superbugs and the value of its solutions for hospitals.
P/S market segment - Pharma infections
OpGen, Inc. develops and markets molecular diagnostic tests and bioinformatics tools to combat antibiotic-resistant infections. The company's revenue depends on the implementation of its solutions in hospitals. This chart reflects the average valuation in the sector, helping to understand how investors view the potential of OpGen's technologies to address this global problem.
P/S of the market as a whole
OpGen is a molecular diagnostics company that develops and markets tests to detect and combat antibiotic-resistant infections. This chart, showing the average market revenue estimate, helps understand how investors view this company, which is addressing one of the most serious threats to global health.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company OpGen Inc.
OpGen is a molecular diagnostics company focused on combating antibiotic resistance. It develops tests that help quickly identify infections and determine the appropriate treatment. This chart reflects investor expectations for future demand for such diagnostic solutions amid the global threat of superbugs.
%20P%2FS%20OpGen%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-OpGen-Inc.&v=1772513664824 "The graph of the company's future (projected) P/S OpGen Inc.")
Future (projected) P/S of the market segment - Pharma infections
OpGen, Inc. is a precision medicine company that uses advanced genomics and artificial intelligence to combat antimicrobial resistance. Its products help hospitals track and manage infections. This chart shows the average future sales estimate in the medical diagnostics sector. It helps understand how the market values OpGen's technologies.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20infections&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-infections&v=1772513664833 "Future (projected) P/S market segment graph - Pharma infections")
Future (projected) P/S of the market as a whole
OpGen, Inc. develops and markets molecular diagnostic tests for the rapid detection and treatment of antibiotic-resistant infections. This chart reflects overall investor sentiment. Antibiotic resistance is a major threat to global health, and OpGen's technologies are aimed at addressing it.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513664877 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales OpGen Inc.
This chart illustrates the sales of OpGen, Inc., a company focused on molecular diagnostics and bioinformatics to combat antibiotic-resistant infections. Revenue is generated from sales of its tests and analytical platforms. The trend reflects hospital demand for solutions to rapidly detect dangerous pathogens.
Sales of companies in the market segment - Pharma infections
OpGen, Inc. provides molecular diagnostic tests and bioinformatics solutions to combat antibiotic-resistant infections. This chart reflects the diagnostics market's growth. The company's products help physicians quickly identify pathogens and their drug susceptibility, which is critical to combating one of the major threats to global health.
Overall market sales
OpGen, Inc. provides solutions for molecular diagnostics and combating antibiotic resistance. Demand for its products is driven by hospital budgets and a focus on infection control. This total revenue chart reflects the overall economic climate, which impacts healthcare system funding.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company OpGen Inc.
OpGen specializes in molecular diagnostics to combat antibiotic resistance. The company's future revenue depends on the implementation of its tests in hospitals for rapid infection detection. The chart shows the diagnostics market growth forecast, which is critical for global healthcare.
%20sales%20of%20the%20company%20OpGen%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-OpGen-Inc.&v=1772513664956 "Schedule of future (projected) sales of the company OpGen Inc.")
Future (projected) sales of companies in the market segment - Pharma infections
OpGen is a molecular diagnostics company that develops and markets tests to detect and combat antibiotic-resistant infections. Its products help hospitals quickly identify dangerous pathogens. This chart shows the forecast for the entire diagnostics market, where the problem of antibiotic resistance is becoming increasingly acute.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-infections&v=1772513664960 "Schedule of future (projected) sales of companies in the market segment - Pharma infections")
Future (projected) sales of the market as a whole
OpGen is a molecular diagnostics company developing tests to detect and combat antibiotic-resistant infections. Demand for their products is driven by the growing global problem of antibiotic resistance. This trend, reflecting healthcare system budgets, affects hospitals' willingness to implement advanced diagnostic solutions.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513665012 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality OpGen Inc.
OpGen specializes in the development and sale of molecular diagnostic tests to combat antibiotic-resistant infections. The company's profitability depends on the adoption of its products in hospitals and laboratories. This chart shows the financial results of a company solving one of the most pressing problems in modern healthcare, and the challenges of commercializing such solutions.
Market segment marginality - Pharma infections
OpGen is a precision medicine company that develops and markets molecular diagnostic tests and bioinformatics solutions to combat antibiotic-resistant infections. Profitability depends on the adoption of their products in hospitals. This chart shows the financial results of their efforts to commercialize technologies in a critical area of healthcare.
Market marginality as a whole
OpGen is a molecular diagnostics company developing tests to detect and combat antibiotic-resistant infections. This is one of the main threats to global health. This overall profitability curve is irrelevant to them. Demand for their products is determined by the severity of the antibiotic resistance problem, not the state of the economy.
Employees in the company, segment and market as a whole
Number of employees in the company OpGen Inc.
OpGen is a molecular diagnostics company focused on combating antibiotic resistance. Its team consists of scientists and diagnostic specialists. The dynamics of this graph reflect its efforts to develop and deploy rapid tests for detecting dangerous infections.
Share of the company's employees OpGen Inc. within the market segment - Pharma infections
OpGen develops and commercializes molecular diagnostic tests to combat antibiotic resistance. This chart reflects the company's presence in this important healthcare sector. It shows the size of its scientific and commercial teams working to implement technologies that help doctors quickly identify effective treatments for infections.
Number of employees in the market segment - Pharma infections
OpGen, Inc. is a precision medicine company using genomics and bioinformatics to combat antibiotic-resistant infectious diseases. This chart illustrates employment trends at the intersection of diagnostics and IT. The growth in bioinformatics specialists reflects the pressing global problem of antibiotic resistance and the need for rapid and accurate diagnostic methods.
Number of employees in the market as a whole
OpGen, Inc. develops solutions to diagnose and combat antibiotic-resistant infections. Demand for its products is driven by healthcare system priorities. Overall economic growth, as seen in this graph, allows governments and hospitals to allocate more resources to address critical issues like antibiotic resistance.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company OpGen Inc. (OPGN)
OpGen is a molecular diagnostics company specializing in combating antibiotic resistance (AMR) using rapid diagnostics and AI. It combines hardware, tests, and software. The chart shows how the market values this hybrid approach. The cost per employee reflects the value of their database and the Acuitas AI platform, which assists physicians, not just the value of the lab tests themselves.
%20of%20the%20company%20OpGen%20Inc.%20(OPGN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-OpGen-Inc.-OPGN&v=1772513665157 "Chart of market capitalization per employee (in thousands of dollars) of the company OpGen Inc. (OPGN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma infections
OpGen develops and markets molecular diagnostic tests to combat antibiotic-resistant infections. The company's value lies in its technology platform, which helps doctors quickly select effective treatments. This chart shows how the market perceives the potential of its technologies to address one of the most pressing healthcare challenges.
%20by%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-infections&v=1772513665204 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma infections")
Market capitalization per employee (in thousands of dollars) for the overall market
OpGen, Inc. provides molecular diagnostics and bioinformatics solutions to combat antibiotic-resistant infections. The chart shows the market's valuation of the diagnostics sector. It reflects how the market values their technology for rapid pathogen identification, which is critical to saving lives.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513665236 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company OpGen Inc. (OPGN)
OpGen is a molecular diagnostics company specializing in combating antibiotic resistance. They develop tests that quickly identify infections and their drug susceptibility. This chart illustrates their struggle to commercialize: profit per employee depends on the adoption of their tests in hospitals and payment from insurers.
%20Chart%20OpGen%20Inc.%20(OPGN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-OpGen-Inc.-OPGN&v=1772513665304 "Company Profit Per Employee (in thousands of dollars) Chart OpGen Inc. (OPGN)")
Profit per employee (in thousands of dollars) in the market segment - Pharma infections
OpGen is a molecular diagnostics company focused on combating antibiotic resistance. They develop tests for the rapid detection of infections. This figure reflects the difficulty of commercializing diagnostic products and the high R&D costs in this field.
%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-infections&v=1772513665343 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma infections")
Profit per employee (in thousands of dollars) for the market as a whole
OpGen is a biotech company specializing in diagnosing infections (antibiotic resistance) using AI and sequencing. It's an R&D and service company. This graph likely shows the cost per employee, reflecting the difficulty of commercializing these complex tests in hospitals.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513665358 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee OpGen Inc. (OPGN)
OpGen is a molecular diagnostics company focused on combating antibiotic resistance. This chart shows the commercial potential of its tests. Increased revenue per employee will mean the implementation of its diagnostic platforms in hospitals for rapid infection detection and effective treatment selection.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-OpGen-Inc.-OPGN&v=1772513665372 "Sales chart per company employee OpGen Inc. (OPGN)")
Sales per employee in the market segment - Pharma infections
OpGen (OPGN) is tackling one of the biggest threats to medicine—antibiotic resistance (AMR). They develop diagnostic tests and software (Ares) for the rapid detection of superbugs. This chart shows how much revenue each employee generates from test and data sales, measuring their productivity in the critical diagnostics segment.
Sales per employee for the market as a whole
OpGen (OPGN) is a molecular diagnostics company focused on combating antibiotic resistance by providing tests and IT solutions. It's a knowledge-intensive business. This chart shows how successfully the company generates revenue from selling its tests and software solutions to hospitals and laboratories in a highly competitive environment.
Short shares by company, segment and market as a whole
Shares shorted by company OpGen Inc. (OPGN)
OpGen is a molecular diagnostics company specializing in the detection of infections and antibiotic resistance. The bearish sentiment shown in this chart reflects investor bets that its diagnostic platforms will not be widely adopted by hospitals and that the company will run out of funds.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-OpGen-Inc.-OPGN&v=1772513665425 "Short Shares Chart for the Company OpGen Inc. (OPGN)")
Shares shorted by market segment - Pharma infections
OpGen is combating antimicrobial resistance by developing molecular diagnostic platforms for detecting infections. This indicator measures the overall bearish sentiment in the infectious disease diagnostics sector. It shows the extent to which investors doubt reimbursement models or the speed of adoption of new tests across the industry.
Shares shorted by the overall market
OpGen (OPGN) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing OPGN won't be able to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator OpGen Inc. (OPGN)
This chart for OpGen is a barometer of the fight against "superbugs." The company is developing diagnostics for detecting antibiotic resistance. "Overheating" (above 70) occurs due to news of "superbug" outbreaks. A lack of sales, a persistent cash shortage, and the risk of delisting lead to "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-OpGen-Inc.-OPGN&v=1772513665529 "RSI 14 indicator chart for the company's stock OpGen Inc. (OPGN)")
RSI 14 Market Segment - Pharma infections
OpGen (OPGN) fights "superbugs." They develop molecular tests that quickly identify antibiotic-resistant infections. This chart tracks overall sentiment in the Pharma/Infections sector. It helps investors understand whether OPGN's performance reflects their niche or whether the entire biotech sector is overheated or oversold.
RSI 14 for the overall market
For OpGen, a biotech company, this graph is a lifeline. Its survival depends on funding R&D. During periods of market euphoria, investors are willing to generously fund risky but promising research. During periods of panic, the money supply is turned off, and cash-burning companies risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast OPGN (OpGen Inc.)
OpGen (OPGN) is a molecular diagnostics company whose platform (Acuity) is designed to rapidly identify bacteria and their antibiotic resistance. This chart shows the average 12-month forecast. It reflects analysts' speculative assessment of the company's ability to commercialize this technology and implement it in hospitals to combat superbugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-OPGN-OpGen-Inc.&v=1772513665579 "A chart showing analyst consensus forecasts for the expected stock price. OPGN (OpGen Inc.)")
The difference between the consensus estimate and the actual stock price OPGN (OpGen Inc.)
OpGen (OPGN) is a superbug detective. Their AI platform (Acinetix) helps hospitals track and combat antibiotic-resistant hospital-acquired infections. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their belief in their SaaS "infection control" model.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-OPGN-OpGen-Inc.&v=1772513665614 "A chart showing the difference between the consensus forecast and the actual stock price. OPGN (OpGen Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma infections
OpGen is a diagnostics company that uses AI and genomics to combat "superbugs" (antibiotic resistance). This chart displays analysts' overall expectations for the *entire* infectious disease pharma sector. It shows whether experts believe the smart diagnostics market to combat AMR will grow.
Analysts' consensus forecast for the overall market share price
OpGen (OPGN) is a company fighting "superbugs." They develop diagnostic tests (Unyvero) and an AI platform (Ares) that help doctors quickly identify antibiotic-resistant bacteria. This chart shows the overall risk appetite, reflecting the market's willingness to fund companies whose breakthrough medical technologies are changing the standard of care.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index OpGen Inc.
OpGen is a superbug detective. Their specialty is molecular diagnostics: they are developing (1) tests (Unyvero) for rapid (hours, not days) identification of superbugs and (2) software (Ares) for tracking their spread. This graph is a summary of their implementation history, reflecting their (slow) path to commercialization.
AKIMA Market Segment Index - Pharma infections
OpGen is a detective in the field of pharmaceutical-related infections. They develop diagnostics and AI platforms that help hospitals quickly identify and combat superbugs (antibiotic-resistant bacteria). This chart compares their composite index to the sector, showing how their anti-drug resistance platform outperforms the competition.
The AKIM Index for the overall market
OpGen is a molecular diagnostics company specializing in the detection of infectious diseases and antibiotic resistance. It is undergoing liquidation. This chart, reflecting the market average, is a backdrop. It helps assess how the troubled diagnostics company fared against the backdrop of overall macroeconomic trends.
